These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33405480)

  • 1. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications.
    Bassetti M; Labate L; Vena A; Giacobbe DR
    Curr Opin Infect Dis; 2021 Apr; 34(2):96-108. PubMed ID: 33405480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
    Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides.
    Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
    Nurse Pract; 2017 May; 42(5):1-6. PubMed ID: 28406838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
    Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
    Soriano A; Rossolini GM; Pea F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
    [No Abstract]   [Full Text] [Related]  

  • 8. Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
    Steuber TD; Gipson H; Boyett B; Belk M; Thayer B; Edwards J
    Int J Antimicrob Agents; 2024 Jun; 63(6):107165. PubMed ID: 38570019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
    Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
    Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
    Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA
    Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of long-acting antibiotics in the clinical practice: a narrative review.
    Micheli G; Chiuchiarelli M; Taccari F; Fantoni M
    Infez Med; 2023; 31(4):449-465. PubMed ID: 38075413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
    Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review.
    Krsak M; Morrisette T; Miller M; Molina K; Huang M; Damioli L; Pisney L; Wong M; Poeschla E
    Pharmacotherapy; 2020 May; 40(5):469-478. PubMed ID: 32239771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.
    Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
    Nurse Pract; 2018 Oct; 43(10):31-37. PubMed ID: 30153191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
    McSorley JC; Reyes D; Tonna I; Bateman V
    Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective.
    Zinzi D; Vlachaki I; Falla E; Mantopoulos T; Nathwani D
    Eur J Health Econ; 2022 Nov; 23(8):1371-1381. PubMed ID: 35113269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
    Klinker KP; Borgert SJ
    Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
    Li R; Nailor MD
    Conn Med; 2016 Mar; 80(3):175-80. PubMed ID: 27169303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
    Ramdeen S; Boucher HW
    Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.